InvestorNews is pleased to announce an upcoming InvestorTalk scheduled for Thursday, April 25th at 9 AM EST, featuring Dave Mehalick, the Chairman, President, and CEO of Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP). To participate in this engaging discussion, please click here

Currently, Coeptis Therapeutics holds 36,089,917 shares outstanding and has a market capitalization of USD$12,631,471.

In preparation for tomorrow’s InvestorTalk, here are the three most recent news releases from Coeptis for your review, which are listed below:

• April 2, 2024 — Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor’s Distinguished Research Award — click here
• February 26, 2024 — Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK — click here
• February 7, 2024 — Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections — click here

5-Data Points from the most recent news release:

1. Recognition of Professor Alexander Deiters: Professor Deiters received the 2024 Chancellor’s Distinguished Research Award from the University of Pittsburgh for his interdisciplinary research in chemistry and biology, underscoring the high impact and innovative nature of his work on the SNAP-CAR platform.
2. Development of SNAP-CAR Technology: The SNAP-CAR T cell therapy platform, co-developed by Professor Alexander Deiters, is significant for its innovative approach in targeting cancer and autoimmune diseases through a universal receptor adaptable to multiple antigens.
3. Expansion of License for Autoimmune Indications: Coeptis Therapeutics expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications for the SNAP-CAR T and NK cell therapies. This expansion highlights the broad potential of SNAP-CAR technology beyond oncology to address significant needs in autoimmune diseases.
4. Pursuit of Phase 2 Program for NK Cell Therapy Against Viral Infections: Coeptis Therapeutics announced plans to initiate a Phase 2 program using DVX201, their proprietary NK cell therapy, targeting severe viral infections such as the “tripledemic” of influenza, COVID-19, and RSV. This highlights the company’s strategic move into infectious disease treatment using innovative cell therapy.
5. Market Growth in Autoimmune Disease Treatments: The global treatment market for autoimmune diseases is projected to grow significantly, from $7.68 billion in 2024 to $12.64 billion in 2028. This indicates a substantial market opportunity for Coeptis Therapeutics’ expanded applications of their SNAP-CAR technology.

(04.24.2024 at 10:40 AM EST, Source)

The last InvestorNews Interview was on March 4, 2024, and was titled: Coeptis’ Dave Mehalick on the disruptive potential of SNAP-CAR technology for autoimmune diseases — click here

InvestorNews is hosting an InvestorTalk this morning with André Larente, CEO, President, and Director from DIAGNOS Inc. (TSXV: ADK | OTCQB: DGNOF) at 9 AM EST. To participate in the InvestorTalk, please click here

DIAGNOS has 76,648,586 shares outstanding and a market cap of CAD$22,994,576.

In preparing for this morning’s InvestorTalk here are the latest news releases for your review:

• April 16, 2024 — DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification — click here
• April 9, 2024 — DIAGNOS Inc. to Present at the Technology Hybrid Investor Conference April 11th — click here
• April 2, 2024 — DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors — click here

5-Data Points from the most recent news release:

1. Approval Process: Diagnos Inc. is working to obtain Health Canada and U.S. FDA approvals for four additional AI analysis modules, with plans to commercialize these during Q3 2024.
2. Module Functions: The new AI modules are designed to assist healthcare professionals in identifying abnormal Optical Coherence Tomography (OCT) retinal images and in grading Fundus images for signs of AMD (Age-Related Macular Degeneration), DR (Diabetic Retinopathy), and HR (Hypertensive Retinopathy).
3. Impact on Revenue and Distribution: The modernization of Diagnos’ Health Canada license is seen as essential for distribution partnerships, including with Essilor Luxottica for the Canadian market, and for potential expansion into the U.S. market. This expansion is expected to accelerate revenue growth for Diagnos.
4. ISO 27001 Certification: Diagnos is also progressing towards obtaining ISO 27001 Cyber Security certification, which is a requirement from current and prospective customers to enhance data security.
5. Company Background and AI Platform: Diagnos is a publicly traded company on the TSX Venture Exchange and the OTCQB. It specializes in early detection of critical health issues using its FLAIRE AI platform, which supports the development and application of AI technologies such as CARA (Computer Assisted Retina Analysis) for enhanced retinal image analysis.

(04.24.2024 – Premarket, Source)

The last InvestorNews Interview was on December 14, 2023, and was titled: Andre Larente from DIAGNOS on Deal with World’s Largest Eyecare Retailer EssilorLuxottica

This week, InvestorNews.com has scheduled two InvestorTalk.com‘s pre-market sessions. On Tuesday, April 9, 2024, Dr. Luisa Moreno from Defense Metals Corp. (TSXV: DEFN | OTCQB: DFMTF) will present from 9-9:20 AM EST. Similarly, on Thursday, April 10, 2024, John Carter from Silver Bullet Mines Corp. (TSXV: SBMI | OTCQB: SBMCF) will present during the same time slot.

In the pre-market scenario, Canadian futures remained flat due to falling oil prices, counteracting gains from rising gold prices. Investors are anticipating a busy week ahead, particularly awaiting the Bank of Canada’s rate decision. Meanwhile, U.S. stock index futures also remained flat, as Treasury yields increased amid speculations of the Federal Reserve delaying policy easing. The U.S. dollar showed minimal movement ahead of the release of U.S. inflation data. European stocks experienced a slight uptick, bolstered by robust industrial production data from Germany. In contrast, Japan’s Nikkei rebounded, closing positively as investors capitalized on buying opportunities following recent market declines.

The Bank of Canada is widely expected to maintain its key overnight rate on hold during its upcoming Wednesday meeting. Analysts suggest that the central bank may wait for more evidence of cooling inflation before implementing its first interest rate cut in four years, potentially in June.

In global markets, Euro STOXX 50 futures were up by 2 points at 4,966, FTSE futures added 8 points to 7,926, and German DAX futures gained 10 points at 18,418 by 0430 GMT. Additionally, oil prices experienced a decline, with Brent falling below $90 as tensions in the Middle East eased.

Spot gold prices were reported at $2,341.79, marking a 0.53% increase equating to $12.29.

Looking back at the U.S. market performance, major averages closed positively on Friday despite a down week overall. The Dow Jones Industrial Average rose by 0.8% following its worst session in over a year. The S&P 500 and Nasdaq Composite also climbed by 1.11% and 1.24%, respectively. Friday’s positive momentum was attributed to the Labor Department’s report, which indicated job growth of 303,000 in March, surpassing expectations.

Federal Reserve Governor Michelle Bowman hinted at potential future rate hikes to control inflation, reflecting a cautious approach amid market uncertainty.

In corporate updates, Catalent Inc. (NYSE: CTLT) and Novo Nordisk A/S refiled their application for approval of a $16.5 billion deal. JPMorgan Chase & Co. CEO Jamie Dimon emphasized U.S. economic strength while opposing stricter bank capital rules proposed by regulators. Perpetua Resources Corp. (NASDAQ: PPTA | TSX: PPTA) received a letter of interest from the U.S. Export-Import Bank for a loan worth up to $1.8 billion. Bristol-Myers Squibb Co reported positive data from late-stage studies of its experimental schizophrenia drug, KarXT, showing symptom reduction without weight gain side effects.

Globally, Janet Yellen concluded meetings in China, advocating for measures to address excess industrial capacity. Additionally, two key U.S. lawmakers reached a deal on draft bipartisan legislation for data privacy, while Peter Pellegrini won Slovakia’s presidential election, reinforcing pro-Russian leadership.

As we catapult into a future shaped by quantum cybersecurity, green hydrogen, and state-of-the-art EV battery technology, the next week’s InvestorTalk events stand as your passport to the bleeding edge of innovation. Set your calendars; these sessions are brimming with insights and revelations.

Quantum eMotion Corp. (TSXV: QNC | OTCQB: QNCCF): On August 15, delve deep into the fabric of quantum mechanics with Francis Bellido. As cyber threats evolve, Quantum eMotion is ensuring our digital fortresses stand impregnable. Their patented Quantum Random Number Generator capitalizes on quantum unpredictability, heralding a new dawn in hardware security. Targets? Everything from Blockchain to Quantum Cryptography.
Click Here to Register for this InvestorTalk at 9 AM EST.

SunHydrogen, Inc. (OTC: HYSR): Imagine powering tomorrow with sunlight and water. On August 16, Tim Young introduces us to the SunHydrogen Panel technology. With an ambition to fuel the emerging $12 trillion hydrogen economy, SunHydrogen aims to drive the future – emission-free.
Click Here to Register for this InvestorTalk at 9 AM EST.

Nano One Materials Corp. (TSX: NANO): That same day, at 4 PM EST, Dan Blondal unveils the green magic behind efficient lithium-ion battery cathode materials. With giants like BASF and Rio Tinto as allies, Nano One’s technology eyes the vast expanse of electric vehicles, energy storage, and consumer electronics Click Here to Register for this InvestorTalk

The Grand InvestorTalk at The National Club: August 17 is an ensemble of visionaries:

• Spencer Huh from NEO Battery Materials Ltd. (TSXV: NBM | OTCQB: NBMFF): Unearthing the potentials of silicon in EV lithium-ion batteries.
• Bundeep Singh Rangar of Fineqia International Inc. (CSE: FNQ): Navigating the future web with digital assets, tokenization, and more.
• Stephen Burega from Romios Gold Resources Inc. (TSXV: RG | OTCQB: RMIOF): From precious metals in the “Golden Triangle” of BC to global mineral explorations – it’s a golden journey.
• Thomas Smeenk of Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF): Introducing blood-based stem cell therapeutics that have the potential to revolutionize healthcare.

RSVP for this event that kicks off at 9:30 AM EST by sending an email to [email protected]

Diving Deeper:

NEO Battery Materials Ltd.: Based in Vancouver, they’re redefining EV battery materials, particularly silicon anode materials, promising enhanced efficiency and capacity over traditional graphite anodes.

Romios Gold Resources Inc.: This Canadian mineral giant, with its vast claims spanning from BC’s “Golden Triangle” to Nevada, merges tradition with innovation in gold, copper, and silver explorations.

Hemostemix: A pioneer in autologous stem cell therapy since 2003, this World Economic Forum Technology Pioneer Award winner is scaling blood-based stem cell therapeutics, which promise groundbreaking treatments.

Fineqia: At the crossroads of the digital revolution, Fineqia is capitalizing on tokenization, blockchain tech, NFTs, AI, and fintech. From managing debt securities in the UK to investing in next-gen Internet technologies, they’re forging digital frontiers.

Prepare for a week of revelations and insights. Whether you’re a seasoned investor, an innovation enthusiast, or someone curious about tomorrow, next week’s InvestorTalks is a trove of enlightenment. Mark your schedule and be part of this journey into the future.

April 24, 2023 — InvestorIntel Corp., a well-known publisher of market news coverage, is pleased to announce the appointment of C.P. Thompson, CFA, MBA, P.Eng., as the Publisher and Editor In Chief. As Publisher and Editor In Chief, Mr. Thompson is responsible for overseeing original content creation, maintaining editorial independence, and expanding InvestorIntel’s online presence as a trusted source of financial market news with over 60 million website visitors annually.

“I am extremely excited to formally take on the role of Publisher and Editor In Chief of InvestorIntel,” Mr. Thompson said. “I have worked with InvestorIntel and founder Tracy Weslosky for several years and have been acting as Publisher and Editor In Chief for the past three months. InvestorIntel continues to bring important stories to the business and investment community, identifying trends before they are reported in other media outlets. This is due to the insight and market knowledge of our world-renown expert writers. Because of this InvestorIntel has grown to be the leader in online news and analysis about critical minerals, ESG, and emerging technologies.”

InvestorIntel Founder, CEO & Director Tracy Weslosky adds: “Chris’ extensive experience in capital markets and financial analysis gives him the in-depth and broad industry knowledge that allows him to identify emerging stories of interest to our wide audience. He has a commitment to well-written independent content and intelligent video interviews that InvestorIntel is focused on.”

Mr. Thompson has been the President and Director of Research at eResearch Corp., a respected source for independent institutional-quality, equity research focused primarily on small- and mid-cap companies. Mr. Thompson has over 15 years of experience in software, financial technology, telecommunications, and information technology. He started his capital markets career in mining equity research at Scotia Capital in 2009 before joining Wellington West Capital Markets in 2010. Subsequently, he spent three years at an NYC-based, investment bank focusing on mergers and acquisitions. Most recently, he was at Global Maxfin Capital, M Partners, and Ubika Research in equity research roles, focusing on the mining, technology, business information, and health technology sectors. In 2019, Chris acquired eResearch Corp., which was founded in 2000. Mr. Thompson holds an Engineering degree from the University of Toronto, an MBA in Investment Management from Concordia University, and is a CFA charterholder.

Mr. Thompson assumes the role of Publisher from Stephen Lautens, who continues with InvestorIntel in the new role of Editor-In-Chief, Special Projects and will join Stephen on the Board of Directors, alongside Tracy Weslosky, and Jack Lifton.

Photo 1: Tracy Weslosky, InvestorIntel Founder, CEO & Director and C.P. Thompson at PDAC 2023

About InvestorIntel Corp.

Celebrating 22 years in business, InvestorIntel Corp. is the Publisher for InvestorIntel.com, an independent financial media and news source focused on capital market coverage. Known for their well-written coverage by top-ranked analysts and business journalists, InvestorIntel.com offers the ii8 System for companies seeking to increase brand awareness through digital media marketing and offers both advertorial video and non-advertorial content. The ii8 System also offers the InvestorIntel.com audience a chance to meet these company CEOs through the Q&A driven InvestorTalk.com event series hosted throughout the week. To subscribe to daily feature columns and ii8 interviews, click here.

For more information, contact Tracy Weslosky @Investor_Intel, +1 416 792 8228 or [email protected].

InvestorIntel Corp. is pleased to announce the appointment of Stephen Lautens as its new Director. He will continue to serve as InvestorIntel’s Publisher and Editor In Chief. As Publisher and Editor In Chief Mr. Lautens is responsible for overseeing content creation, maintaining editorial independence, and expanding InvestorIntel’s online presence as a trusted and number one source of capital market news.

“I am extremely excited to join the board of InvestorIntel,” Mr. Lautens said. “I have worked with InvestorIntel for the past three months as Publisher and Editor In Chief and am always impressed by our world-renown expert writers and the stories they cover. InvestorIntel has grown to be the leader in online news and analysis about critical materials, rare earths, ESG and emerging technologies.”

InvestorIntel Founder, CEO & Director Tracy Weslosky adds: “Authenticity, depth of knowledge and experience are criteria that our audience demands from us, and Stephen delivers all these qualities plus. The long game here is a commitment to performance through well-written independent content and intelligent video interviews that our audience can trust. Stephen joins ESG and Critical Minerals expert Jack Lifton as a Director.”

Mr. Lautens has a wide range of experience in communications, investor relations and business development as part of executive management teams of both private and public companies. He has previously served as VP Corporate Development for a TSXV-listed Canadian exploration company with gold and oil projects in Cambodia. Before that, Mr. Lautens was VP Corporate Communications of Inter-Citic Minerals Inc. for almost eight years. Inter-Citic was a TSX-listed gold exploration company with a large project in western China that sold for $260 million in cash in a friendly takeover in November 2012 to Western Mining Co Ltd, a $5.5B mining company based in China, at a 123% premium to market share price.

Previously, Mr. Lautens worked as Executive VP of a company developing a project in partnership with China Minmetals Non-Ferrous Metals Co. Ltd., then one of China’s largest State Owned Enterprises. He also served as VP Business Development of The Workflow Automation Corporation, a private Canadian software technology company acquired by BEA Systems, Inc. (since acquired by Oracle) in 2000 for $46 million.

Stephen Lautens has been Governor of The National Newspaper Awards for over 10  years and is a past president of The National Club. Mr. Lautens was also president of the Lawyers Club and served two terms as president of the Toronto Press Club. He wrote a syndicated weekly column for almost 20 years, and his articles have appeared in numerous publications, including Canadian Lawyer Magazine, The National Post, The Calgary Sun, The London Free Press and The Toronto Sun. Prior to entering business, Mr. Lautens had his own law practice for over 10 years.

In 2012 Stephen Lautens was awarded the Queen Elizabeth II Diamond Jubilee Medal for his community and charity work. Among his other international honours, he was granted the Freedom of the City of London (UK) in 2008 and received the “Flame of Mercy” award from the CSLI – an international humanitarian NGO with Consultative Status at the United Nations, ECOSOC.

He earned a J.D. degree from Queen’s Law School, Kingston, and a history B.A. degree from Victoria College at the University of Toronto. Mr. Lautens lives in and will be based in Toronto.

About InvestorIntel Corp.

Celebrating 21 years in business, InvestorIntel Corp. is the Publisher for InvestorIntel.com — “your independent source of capital market news.” Known for their well-written coverage of the public markets written by top-ranked analysts and business journalists, InvestorIntel.com offers an ii8 System for public companies seeking to increase brand awareness through digital media marketing. The ii8 System features regular video updates by CEOs with well-known market hosts and offers the InvestorIntel.com audience a chance to meet these company CEOs through the Q&A driven InvestorTalk.com event series hosted throughout the week. To subscribe to daily feature columns and ii8 interviews, click here.

For more information, contact Tracy Weslosky @Investor_Intel, +1 416 792 8228 or [email protected].